EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Gap analysis FDA data Peer-reviewed Educational calculation

Why the evidence for botanicals is thin

Few botanical drugs reach FDA approval, and many botanical trials are small, fragile or inconclusive. FDA data and research on trial methods point to causes that can be measured.

About half of the 739 botanical INDs FDA received 1984–2020 had been withdrawn or terminated by December 2020FDA authors, 2025

Status in December 2020: 253 of 739 INDs were active, 374 withdrawn or terminated.

Data table: botanical INDs by indication, first FDA action and status
Botanical INDs received March 1984 to December 2020, FDA initial 30-day action and regulatory status in December 2020 (Park et al. 2025, Table 1)
IndicationINDsSafe to proceedClinical holdWithdrawnOther first actionActive, 2020On holdWithdrawn or terminatedInactiveOther status
Oncology254175561211827137244
Other indications4852821111478171332373113
All botanical INDs7394571672689253403745517
Oncology botanical INDs by initially proposed phase (Park et al. 2025, Results and Fig. 1)
Proposed phaseINDsActive, December 2020Not activeActive share
Phase 1137469134%
Phase 2111337830%
Phase 363350%
An IND (investigational new drug application) lets a sponsor test an unapproved drug in people. The IND counts end in December 2020; the four approvals run from 2006 to 2023, all for non-cancer uses, and are not linked to individual INDs in the source. “Not active” covers hold, withdrawn or terminated, inactive and other statuses.Park JK, Lee D, Rui L, Gao X, Furness MS, Wu C. Ther Innov Regul Sci 2025;59:1129–1137 (FDA authors; FDA CDER Botanical Review Team database), Table 1, Results and Fig. 1. FDA CDER, What is a Botanical Drug? (content current as of September 3, 2026).

Status. EUTECNIQ Sciences is a company in formation with no trials, data or products of its own. Every result here is published third-party work or the site's own editorial grading; the last section labels EUTECNIQ's role as a proposal.

Related: the four botanical drugs · evidence and pharmacokinetics · proof nobody can own · lessons from large trials

Why so few approvals

Two routes to market, one of them without efficacy trials

A botanical drug must prove efficacy and batch-to-batch consistency; a botanical supplement reaches the market with no FDA approval at all.

What each U.S. route asks for before and after a botanical product is soldFDA guidance and statute
Two routes: a botanical drug passes Phase 1–2 and Phase 3 IND trials and an NDA review of efficacy and batch consistency; a supplement may need only a safety notification for a new ingredient, a claim notification and a disclaimer, with no FDA approval before saleBefore saleOn the marketBotanical drugFDA approvalrequiredIND, Phase 1–2Raw materials and priorhuman use described;typical Phase 1 tolerabilitystudies generally notneeded for a product soldas a supplementIND, Phase 3Several product batches,each from a differentdrug-substance batch;added toxicology dataNDA reviewEfficacy shown in trials;batch consistency by thetotality of the evidenceApproved drugLabeled for a disease use;four botanical drugs,2006–2023DietarysupplementNo approvalNew dietary ingredient?If new to the food supply, asafety notification 75 daysbefore sale (21 CFR 190.6);no efficacy reviewStructure/function claimFirm holds substantiation;notifies FDA within 30 days;label disclaimer (21 CFR101.93)On saleNo FDA approval beforemarketing (DSHEA); nodisease claimsNo efficacy reviewbefore saleTwo routes: a botanical drug passes IND trials and an NDA review of efficacy and batch consistency; a supplement may need only notifications and a disclaimer, with no FDA approval before saleBotanical drug: FDA approval requiredIND, Phase 1–2Raw materials and prior human use described; typicalPhase 1 tolerability studies generally not needed for aproduct sold as a supplementIND, Phase 3Several product batches, each from a differentdrug-substance batch; added toxicology dataNDA reviewEfficacy shown in trials; batch consistency by thetotality of the evidenceApproved drugLabeled for a disease use; four botanical drugs,2006–2023Dietary supplement: no approvalNew dietary ingredient?If new to the food supply, a safety notification 75days before sale (21 CFR 190.6); no efficacy reviewStructure/function claimFirm holds substantiation; notifies FDA within 30days; label disclaimer (21 CFR 101.93)On saleNo FDA approval before marketing (DSHEA); nodisease claims
Drug route: FDA guidance (nonbinding recommendations, final, December 2016) on top of the binding IND and NDA rules. Supplement route: statute and regulation. Schematic, not to scale.FDA CDER, Botanical Drug Development: Guidance for Industry, Revision 1, December 2016, Sections III.B, V.A, V.E, VI.A and VII. FDA, Questions and Answers on Dietary Supplements (content current as of August 27, 2026). 21 CFR 190.6; 21 CFR 101.93.
$2,558Maverage capitalized pre-approval cost per approved new drug, 106 drugs from 10 firms, 2013 dollars
$1,142Mmedian capitalized R&D cost per new drug, 63 FDA approvals 2009–2018, 2018 dollars (corrected 2022)
£92,500to make GMP trial capsules of one herbal extract for 382 patients, over more than 2 years

DiMasi JA, Grabowski HG, Hansen RW. J Health Econ 2016;47:20–33 (abstract). Wouters OJ, McKee M, Luyten J. JAMA 2020;323(9):844–853, corrected version (correction notice JAMA 2022;328(11):1111). Bourqui A, et al. Front Pharmacol 2026;17:1766381, opinion article, section 4 (the authors' uva-ursi trial, UK).

The cost of proof lands on one sponsor, while a supplement seller can market the same plant without it; the FDA authors name insufficient raw-material information, the variation and complexity of botanical components and the evidence needed for approval as the main challenges.

Explanation, details and sources

What the 2016 guidance asks. Because a botanical drug is a mixture whose active constituents may be unknown, FDA says “one of the critical issues for botanical drugs is ensuring that the therapeutic effect for marketed drug product batches is consistent.” It supports that consistency with a “totality of the evidence” approach: raw-material control (agricultural practice and collection), chemical tests with manufacturing control and process validation, and a biological assay with clinical data (Section III.B). In Phase 3 it suggests testing several drug-product batches, each made from a different drug-substance batch (Section VI.A), and “highly recommended” randomizing subjects to batches at each site (Section VI.F.1).

Where it is flexible. Early clinical evaluation “does not differ significantly” from that of purified drugs, and products already marketed as supplements “generally would not require typical Phase 1 tolerability studies” when prior human use is shown to be relevant (Section V.E). The Phase 3 and NDA steps carry the extra burden.

What the FDA authors report. Park et al. list “insufficient information on botanical raw materials, which often leads to trial holds or withdrawals in early-phase studies,” “the inherent variation and complexity of botanical components” and “the rigorous evidence-based requirements necessary for drug approval.” Terminations “often occurred when methods, facilities, and controls used for manufacturing the products were inadequate.” They set the share of oncology INDs still active in December 2020, 34% for Phase 1 and 30% for Phase 2, beside published success rates of 66% and 49% for conventional Phase 1 and 2 INDs, and write that the probability of success “seemed lower”; the botanical figure is a share still active, not a count of programs that advanced. Of the oncology INDs, 24% were commercial applications; the authors put research applications from clinical investigators at 76% (data not shown in the paper).

Earlier FDA count. In 2020, FDA's Botanical Review Team reported “over 800” botanical INDs and pre-IND meeting requests before 2018, with two botanical NDAs then approved (Wu et al. 2020). The 739 above exclude pre-IND requests and cover 1984 to 2020.

The supplement route. “Under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed” (FDA Q&A). A new dietary ingredient that has not been in the food supply in an unaltered form needs a premarket notification at least 75 days before marketing, setting out why it “will reasonably be expected to be safe” (21 CFR 190.6); there is no efficacy review. A structure/function claim needs substantiation held by the firm, a notice to FDA within 30 days of marketing, and the label disclaimer that the statement “has not been evaluated by the Food and Drug Administration” (21 CFR 101.93). Who can and cannot protect the cost of a trial is set out on the food–drug gap page; how often drug programs of any kind reach approval is on the drug pathway.

Cost figures. DiMasi et al. estimated an average out-of-pocket cost of $1,395 million per approved compound, capitalized at a 10.5% real discount rate to $2,558 million (2013 dollars). Wouters et al., in the version corrected in 2022 after an error in a source of clinical-trial success rates, estimated a median of $1,141.7 million (95% CI $888.1–1,480.8 million) and a mean of $1,559.1 million (2018 dollars), after accounting for failed trials; the data came mainly from smaller firms and orphan, first-in-class and accelerated-approval products. The originally published figures were $985.3 million and $1,335.9 million. Neither study is specific to botanicals. In the UK trial Bourqui et al. describe, no GMP uva-ursi product was on the market, so the team had an extract made and encapsulated under GMP, “costing £92,500 to produce enough capsules to treat 382 patients … and taking over 2 years.”

Park et al. 2025 (PMC12446141); Wu C, Lee SL, Taylor C, et al. J Nat Prod 2020;83(2):552–562; FDA Botanical Drug Development guidance (2016); FDA Q&A on Dietary Supplements; eCFR 21 CFR 190.6 and 101.93; DiMasi et al. 2016; Wouters et al. 2020 (corrected 2022); Bourqui et al. 2026 (opinion article).

Root causes

Seven causes behind “no significant difference”

A null result in a botanical trial can come from the product, the design, the dose reaching the body or the record, before the plant itself is judged.

Cause-and-effect (Ishikawa) diagram: why human data on botanicals are limited and often inconclusive, each cause with a measured examplePeer-reviewed sources
Cause-and-effect diagram: seven groups of causes, product variation, small trials, incomplete reports, unclear endpoints and populations, low exposure, positive-result bias and weak incentives, lead to limited human data and small, fragile or inconclusive trialsLimited human dataSmall, fragile orinconclusive trialsProduct variesGinsenosides varied 15-to 36-fold across 25ginseng products [1]6 of 59 echinaceaproducts: nonemeasurable [2]12 of 81 RCTs reportedtesting content [3]Trials are smallMedian 115 participants,227 Chinese herbal RCTs[4]Half of 30 positive IBStrials hinge on one patient[5]Trials under 50 patients:effects 48% larger than intrials of 1,000+ [7]Reports are incomplete45% of CONSORT itemsreported, 206 RCTs [8]Concealmentincompletely reported;constituent content maybe missing [8]Endpoints, populations40.5% of 227 RCTs set noclear primary outcome [4]Country differences mayreflect patient types [6]Too little reaches bloodNo parent curcumin inserum at 0.5–8 g [10]Absorbed is not the sameas effectivePositive-result biasAll acupuncture trials fromfour countries positive [11]German-speaking trialsmore favorable [6]Few reasons to payNo FDA approval neededto sell a supplement [12]Opinion: hard to patent;no reason to obtain GMP[13]Cause-and-effect diagram, phone layout: seven groups of causes along a vertical spine lead to limited human data and small, fragile or inconclusive trialsProduct variesGinsenosides varied 15- to 36-fold across 25ginseng products [1]6 of 59 echinacea products: none measurable [2]12 of 81 RCTs reported testing content [3]Trials are smallMedian 115 participants, 227 Chinese herbal RCTs[4]Half of 30 positive IBS trials hinge on one patient[5]Trials under 50 patients: effects 48% larger than intrials of 1,000+ [7]Reports are incomplete45% of CONSORT items reported, 206 RCTs [8]Concealment incompletely reported; constituentcontent may be missing [8]Endpoints, populations40.5% of 227 RCTs set no clear primary outcome[4]Country differences may reflect patient types [6]Too little reaches bloodNo parent curcumin in serum at 0.5–8 g [10]Absorbed is not the same as effectivePositive-result biasAll acupuncture trials from four countries positive[11]German-speaking trials more favorable [6]Few reasons to payNo FDA approval needed to sell a supplement [12]Opinion: hard to patent; no reason to obtain GMP[13]Limited human dataSmall, fragile or inconclusive trials
Numbers in brackets refer to the sources listed in the text version. The diagram groups published findings; it does not weight the causes or claim they explain any one trial.Harkey 2001; Gilroy 2003; Wolsko 2005; Hu 2021; Luo 2024; Linde 2008; Dechartres 2013; Gagnier 2006 (two papers); Lao 2006; Vickers 1998; Bourqui 2026; FDA Q&A on Dietary Supplements.

Product variation, low exposure and small samples make a real effect harder to detect; small-study and country effects push the other way, toward larger effects than large trials report.

Text version: the seven causes and their sources
  1. The product varies. In 25 U.S. ginseng products, ginsenoside concentrations varied 15-fold in capsules and 36-fold in liquids, and eleutherosides 43- and 200-fold [1]. Of 59 echinacea preparations, 6 (10%) contained no measurable echinacea, and 9 of 21 labeled “standardized” (43%) met their label standard [2]. Of 81 RCTs of five herbs published 2000–2004, 12 (15%) reported testing the content of the product studied [3].
  2. Trials are small. In 227 Chinese herbal medicine RCTs published in English 2010–2019 (a random 20% of those eligible), the median sample size was 115 participants (range 12 to 3,143) [4]. In 30 herbal RCTs for irritable bowel syndrome with a positive binary outcome, the median fragility index was 1.5, and half the trials would lose significance if one patient's outcome changed [5]. In a Cochrane review of St John's wort, nine larger placebo-controlled trials gave a response ratio of 1.28 and nine smaller ones 1.87 [6]. Across 93 meta-analyses of therapies of all kinds (binary outcomes), trials with fewer than 50 patients showed effects 48% larger, on average, than trials of 1,000 or more [7].
  3. Reports leave out what matters. Across 206 herbal RCTs, 45% of CONSORT checklist items were reported; allocation concealment, sequence generation and intention-to-treat were incompletely reported, and the percentage of active constituents may be missing [8]. In 2006 the CONSORT group elaborated 9 checklist items for herbal trials; item 4, the herbal intervention, “required the most extensive elaboration” [9].
  4. Endpoints and populations are unclear. In the 227-trial sample, 40.5% did not clearly specify any primary outcome and 24.7% did not report any adverse event [4]. In the St John's wort review, trials from German-speaking countries reported results more favorable to the extract; the review's plain-language summary says this “could be due to the inclusion of patients with slightly different types of depression, but it cannot be ruled out that some smaller studies from German‐speaking countries were flawed and reported overoptimistic results” [6].
  5. Too little reaches the blood. After single doses of 0.5 to 8 g of a standardized curcuminoid powder extract, no curcumin (the parent compound) was detected in serum; at 10 and 12 g low levels were found in 1 of 3 volunteers at each dose [10]. Metabolites are another matter, charted with the absorption data on Evidence and pharmacokinetics.
  6. Positive results are overrepresented. In a review of controlled-trial abstracts to 1995, every acupuncture trial from China, Japan, Hong Kong and Taiwan was positive; among trials of other interventions, 99% of those published in China and 75% of those published in England favored the test treatment, and no trial from China or Russia/USSR found a treatment ineffective [11].
  7. Few have a reason to pay. FDA has no authority to approve supplements before marketing [12]. In an opinion article, Swiss and UK trial teams write that companies are reluctant to disclose production details partly because herbal food supplements “are difficult to patent,” and that companies have “no reason to obtain GMP certification,” which clinical-trial products need in Switzerland and, for full-scale trials, in the UK [13]. Patent and exclusivity law is set out on the food–drug gap page.
  1. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001;73(6):1101–1106.
  2. Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Arch Intern Med 2003;163(6):699–704.
  3. Wolsko PM, Solondz DK, Phillips RS, Schachter SC, Eisenberg DM. Lack of herbal supplement characterization in published randomized controlled trials. Am J Med 2005;118(10):1087–1093.
  4. Hu J, Zhang HN, Feng S, et al. Randomized controlled trials of Chinese herbal medicine published in English from 2010 to 2019: a bibliometrics study. Ann Palliat Med 2021;10(12):12945–12954.
  5. Luo M, Huang J, Wang Y, et al. How fragile the positive results of Chinese herbal medicine randomized controlled trials on irritable bowel syndrome are? BMC Complement Med Ther 2024;24:300.
  6. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008;(4):CD000448.
  7. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304.
  8. Gagnier JJ, DeMelo J, Boon H, Rochon P, Bombardier C. Quality of reporting of randomized controlled trials of herbal medicine interventions. Am J Med 2006;119(9):800.e1–11.
  9. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 2006;144(5):364–367.
  10. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10.
  11. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 1998;19(2):159–166.
  12. FDA. Questions and Answers on Dietary Supplements (content current as of August 27, 2026).
  13. Bourqui A, Csajka C, Heinrich M, et al. Challenges in performing clinical research on herbal products: experiences from Switzerland and the UK. Front Pharmacol 2026;17:1766381 (opinion article).
Statistical power

Why a 30-per-arm trial usually misses a small effect

Power is the chance that a trial detects an effect that is really there; with 30 people per arm and a small effect (d = 0.2), it is 12.1%, about one in 8.

Interactive calculator Change the inputs and the result updates. An educational simulation with stated inputs.

Power12.1%
Chance of a non-significant result87.9%
Per arm for 80% power393
Smallest d with 80% power at this n0.72

At 30 per arm, a real effect of d = 0.20 gives a non-significant result 88% of the time.

Power against participants per arm, two-sample comparison of meansEducational calculation
Lines for d = 0.2, 0.5 and 0.8 are Cohen's conventional small, medium and large effects; the bold line follows the slider. Dashed line: 80% power, the conventional minimum.
Two-sample test of means, normal approximation (equal arms, known common SD)Power ≈ Φ(d·√(n/2) − z1−α/2) + Φ(−d·√(n/2) − z1−α/2)  ·  nper arm = 2(z1−α/2 + z1−β)² ⁄ d²
Method, assumptions and limits
What it calculates
The probability that a two-arm randomized trial with a continuous outcome reaches a two-sided significant result, given the true standardized effect, the number per arm and α; the number per arm for 80% power; and the smallest effect that has 80% power at the chosen number.
Equations
Power = Φ(d·√(n/2) − z1−α/2) + Φ(−d·√(n/2) − z1−α/2), where Φ is the standard normal distribution function and zq its quantile. Solving for n at power 1 − β (neglecting the second, very small term) gives n = 2(z1−α/2 + z1−β)²/d², rounded up; this is the per-group formula n = (Zα/2 + Zβ)²·2σ²/(μ1 − μ2)² of Sakpal (2010) with d = (μ1 − μ2)/σ. Smallest detectable d = (z1−α/2 + z0.80)·√(2/n).
Variables and units
d: true difference in means divided by the common standard deviation (dimensionless), 0.05 to 1.5. n: participants analyzed per arm, 4 to 1,000. α: two-sided significance level.
Assumptions
Two equal arms, one continuous primary outcome, normally distributed with equal variances, independent participants, no dropout, one test. The normal approximation slightly overstates power at small n compared with the exact t-test (table below).
Valid range
Use n of about 10 or more per arm for the approximation; below that the exact noncentral t calculation gives noticeably lower power.
What it does not establish
It does not say what effect a botanical has. The effect sizes are inputs, not estimates for any product, and conventions such as d = 0.2 for “small” are arbitrary and should not be read rigidly (Lakens 2013).
Verification
Checked against statsmodels 0.15 NormalIndPower (same formula) and TTestIndPower (exact noncentral t); the calculator is checked against an independent scipy implementation
Power at α = 0.05 (two-sided): this calculator against statsmodels
dn per armNormal approximation (this page)statsmodels NormalIndPowerstatsmodels TTestIndPower (exact t)
0.2107.3%7.3%7.1%
0.23012.1%12.1%11.9%
0.210029.3%29.3%29.1%
0.240080.7%80.7%80.6%
0.51020.1%20.1%18.5%
0.53049.1%49.1%47.8%
0.510094.2%94.2%94.0%
0.5400100.0%100.0%100.0%
0.81043.2%43.2%39.5%
0.83087.3%87.3%86.1%
0.8100100.0%100.0%100.0%
0.8400100.0%100.0%100.0%
References
Sakpal TV. Sample size estimation in clinical trial. Perspect Clin Res 2010;1(2):67–69. Lakens D. Calculating and reporting effect sizes to facilitate cumulative science. Front Psychol 2013;4:863 (benchmarks d = 0.2, 0.5, 0.8 after Cohen 1988; power 0.80 as the accepted minimum). Button KS, Ioannidis JPA, Mokrysz C, et al. Power failure. Nat Rev Neurosci 2013;14:365–376.

A non-significant result from an underpowered trial is weak evidence of no effect; low power also inflates the effects that do reach significance (Button et al. 2013).

This site's own data

72.8% of graded findings on this site are C or X

Of 1,071 graded findings on 264 ingredients, 72.8% are graded C or X and 24.8% A or B. Botanicals carry 522 of the rows: 76% C, 3% X and 0.8% A.

1,071evidence rows graded across 264 ingredients in the site's Supplements A–Z
64.9%of rows graded C, limited human evidence (695 rows)
7.9%graded X, well-designed trials found no meaningful effect (85 rows)
2.5%graded A, consistent results from several randomized trials (27 rows)
Evidence grade of each graded finding, and evidence class of each ingredientSite data, editorial grades
Bars: of 1071 graded findings, 27 are A, 239 B, 695 C, 25 D and 85 X; of 264 ingredients, 173 are class 1, 66 are class 2, 22 are class 3, 3 are class 4Grade of 1071 findings0175350525700A · Consistent RCTs: 27 findings27A ·ConsistentRCTsB · Some positive RCTs: 239 findings239B · SomepositiveRCTsC · Limited: 695 findings695C · LimitedD · Lab or animal: 25 findings25D · Lab oranimalX · No effect in good trials: 85 findings85X · No effectin good trialsEvidence class of 264 ingredients0501001502001 · Well studied in people: 173 ingredients1731 · Well studiedin people2 · Moderately studied in people: 66 ingredients662 · Moderatelystudied in people3 · Limited studies in people: 22 ingredients223 · Limitedstudies in people4 · Animal studies only: 3 ingredients34 · Animalstudies onlyBars: of 1071 graded findings, 27 are A, 239 B, 695 C, 25 D and 85 X; of 264 ingredients, 173 are class 1, 66 are class 2, 22 are class 3, 3 are class 4Grade of 1071 findings0175350525700A: 27 findings27AB: 239 findings239BC: 695 findings695CD: 25 findings25DX: 85 findings85XEvidence class of 264 ingredients050100150200Class 1: 173 ingredients173Class 1Class 2: 66 ingredients66Class 2Class 3: 22 ingredients22Class 3Class 4: 3 ingredients3Class 4
Data tables: grades and classes
Evidence grades of all graded findings
GradeDefinition used on this siteFindingsShare
AConsistent results from several randomized trials or a systematic review of them272.5%
BSome positive randomized trials, but small, short, few or inconsistent23922.3%
CLimited human evidence: single small trials, observational data or mixed results69564.9%
DLaboratory or animal evidence only; not shown in people252.3%
XWell-designed human trials found no meaningful effect857.9%
Evidence class of each ingredient (amount of human research on the ingredient taken alone)
ClassDefinitionIngredientsShare
Class 1Well studied in people17365.5%
Class 2Moderately studied in people6625.0%
Class 3Limited studies in people228.3%
Class 4Animal studies only31.1%
Grades and classes are this site's editorial judgments of the cited sources (definitions on How to judge a supplement), not a census of the literature or a regulatory measure. Each ingredient carries 1 to 7 graded topics chosen from what human research has studied.EUTECNIQ Supplements A–Z data, computed with pandas on October 30, 2026.
Share of each category's findings at each grade: botanicals 76% C; highest X share in the vitamin category, 31% Site data, editorial grades
Heat map of grade shares by ingredient category: Botanical 76% C and 3% X of 522; Other 57% C and 9% X of 188; Amino acid and protein 45% C and 8% X of 85; Vitamin 50% C and 31% X of 70; Probiotic 42% C and 19% X of 59; Mineral 53% C and 10% X of 49; Fatty acid 46% C and 22% X of 37; Marine and algae 75% C and 0% X of 32; Mushroom 83% C and 0% X of 29Category (findings)A ·ConsistentRCTsB · SomepositiveRCTsC · LimitedD · Lab oranimalX · No effectin good trialsBotanical (522)Botanical, grade A: 4 of 522 findings (1%)1%Botanical, grade B: 87 of 522 findings (17%)17%Botanical, grade C: 398 of 522 findings (76%)76%Botanical, grade D: 17 of 522 findings (3%)3%Botanical, grade X: 16 of 522 findings (3%)3%Other (188)Other, grade A: 10 of 188 findings (5%)5%Other, grade B: 53 of 188 findings (28%)28%Other, grade C: 108 of 188 findings (57%)57%Other, grade D: 1 of 188 findings (1%)1%Other, grade X: 16 of 188 findings (9%)9%Amino acid and protein (85)Amino acid and protein, grade A: 2 of 85 findings (2%)2%Amino acid and protein, grade B: 36 of 85 findings (42%)42%Amino acid and protein, grade C: 38 of 85 findings (45%)45%Amino acid and protein, grade D: 2 of 85 findings (2%)2%Amino acid and protein, grade X: 7 of 85 findings (8%)8%Vitamin (70)Vitamin, grade A: 4 of 70 findings (6%)6%Vitamin, grade B: 9 of 70 findings (13%)13%Vitamin, grade C: 35 of 70 findings (50%)50%Vitamin, grade D: 0 of 70 findings (0%)0%Vitamin, grade X: 22 of 70 findings (31%)31%Probiotic (59)Probiotic, grade A: 1 of 59 findings (2%)2%Probiotic, grade B: 22 of 59 findings (37%)37%Probiotic, grade C: 25 of 59 findings (42%)42%Probiotic, grade D: 0 of 59 findings (0%)0%Probiotic, grade X: 11 of 59 findings (19%)19%Mineral (49)Mineral, grade A: 4 of 49 findings (8%)8%Mineral, grade B: 14 of 49 findings (29%)29%Mineral, grade C: 26 of 49 findings (53%)53%Mineral, grade D: 0 of 49 findings (0%)0%Mineral, grade X: 5 of 49 findings (10%)10%Fatty acid (37)Fatty acid, grade A: 2 of 37 findings (5%)5%Fatty acid, grade B: 10 of 37 findings (27%)27%Fatty acid, grade C: 17 of 37 findings (46%)46%Fatty acid, grade D: 0 of 37 findings (0%)0%Fatty acid, grade X: 8 of 37 findings (22%)22%Marine and algae (32)Marine and algae, grade A: 0 of 32 findings (0%)0%Marine and algae, grade B: 6 of 32 findings (19%)19%Marine and algae, grade C: 24 of 32 findings (75%)75%Marine and algae, grade D: 2 of 32 findings (6%)6%Marine and algae, grade X: 0 of 32 findings (0%)0%Mushroom (29)Mushroom, grade A: 0 of 29 findings (0%)0%Mushroom, grade B: 2 of 29 findings (7%)7%Mushroom, grade C: 24 of 29 findings (83%)83%Mushroom, grade D: 3 of 29 findings (10%)10%Mushroom, grade X: 0 of 29 findings (0%)0%Share of the row's findings0%100%Heat map of grade shares by ingredient category: Botanical 76% C and 3% X of 522; Other 57% C and 9% X of 188; Amino acid and protein 45% C and 8% X of 85; Vitamin 50% C and 31% X of 70; Probiotic 42% C and 19% X of 59; Mineral 53% C and 10% X of 49; Fatty acid 46% C and 22% X of 37; Marine and algae 75% C and 0% X of 32; Mushroom 83% C and 0% X of 29Category (findings)ABCDXBotanical (522)Botanical, grade A: 4 of 522 findings (1%)1%Botanical, grade B: 87 of 522 findings (17%)17%Botanical, grade C: 398 of 522 findings (76%)76%Botanical, grade D: 17 of 522 findings (3%)3%Botanical, grade X: 16 of 522 findings (3%)3%Other (188)Other, grade A: 10 of 188 findings (5%)5%Other, grade B: 53 of 188 findings (28%)28%Other, grade C: 108 of 188 findings (57%)57%Other, grade D: 1 of 188 findings (1%)1%Other, grade X: 16 of 188 findings (9%)9%Amino acid and protein(85)Amino acid and protein, grade A: 2 of 85 findings (2%)2%Amino acid and protein, grade B: 36 of 85 findings (42%)42%Amino acid and protein, grade C: 38 of 85 findings (45%)45%Amino acid and protein, grade D: 2 of 85 findings (2%)2%Amino acid and protein, grade X: 7 of 85 findings (8%)8%Vitamin (70)Vitamin, grade A: 4 of 70 findings (6%)6%Vitamin, grade B: 9 of 70 findings (13%)13%Vitamin, grade C: 35 of 70 findings (50%)50%Vitamin, grade D: 0 of 70 findings (0%)0%Vitamin, grade X: 22 of 70 findings (31%)31%Probiotic (59)Probiotic, grade A: 1 of 59 findings (2%)2%Probiotic, grade B: 22 of 59 findings (37%)37%Probiotic, grade C: 25 of 59 findings (42%)42%Probiotic, grade D: 0 of 59 findings (0%)0%Probiotic, grade X: 11 of 59 findings (19%)19%Mineral (49)Mineral, grade A: 4 of 49 findings (8%)8%Mineral, grade B: 14 of 49 findings (29%)29%Mineral, grade C: 26 of 49 findings (53%)53%Mineral, grade D: 0 of 49 findings (0%)0%Mineral, grade X: 5 of 49 findings (10%)10%Fatty acid (37)Fatty acid, grade A: 2 of 37 findings (5%)5%Fatty acid, grade B: 10 of 37 findings (27%)27%Fatty acid, grade C: 17 of 37 findings (46%)46%Fatty acid, grade D: 0 of 37 findings (0%)0%Fatty acid, grade X: 8 of 37 findings (22%)22%Marine and algae (32)Marine and algae, grade A: 0 of 32 findings (0%)0%Marine and algae, grade B: 6 of 32 findings (19%)19%Marine and algae, grade C: 24 of 32 findings (75%)75%Marine and algae, grade D: 2 of 32 findings (6%)6%Marine and algae, grade X: 0 of 32 findings (0%)0%Mushroom (29)Mushroom, grade A: 0 of 29 findings (0%)0%Mushroom, grade B: 2 of 29 findings (7%)7%Mushroom, grade C: 24 of 29 findings (83%)83%Mushroom, grade D: 3 of 29 findings (10%)10%Mushroom, grade X: 0 of 29 findings (0%)0%Share of the row's findings0%100%
Data table: grade by category
Findings by ingredient category and grade (count and row share)
CategoryIngredientsFindingsABCDXC or X
Botanical1305224 (1%)87 (17%)398 (76%)17 (3%)16 (3%)79%
Other4418810 (5%)53 (28%)108 (57%)1 (1%)16 (9%)66%
Amino acid and protein21852 (2%)36 (42%)38 (45%)2 (2%)7 (8%)53%
Vitamin18704 (6%)9 (13%)35 (50%)0 (0%)22 (31%)81%
Probiotic11591 (2%)22 (37%)25 (42%)0 (0%)11 (19%)61%
Mineral13494 (8%)14 (29%)26 (53%)0 (0%)5 (10%)63%
Fatty acid10372 (5%)10 (27%)17 (46%)0 (0%)8 (22%)68%
Marine and algae10320 (0%)6 (19%)24 (75%)2 (6%)0 (0%)75%
Mushroom7290 (0%)2 (7%)24 (83%)3 (10%)0 (0%)83%
Each row sums to 100% of that category's graded findings; the count of findings is shown with each row label.EUTECNIQ Supplements A–Z data.
Share of findings at each grade by the effect studied, for effects with 10 or more graded findingsSite data, editorial grades
Heat map of grade shares by studied effect for effects with 10 or more findings; the data table lists every valueEffect studied (findings)A ·ConsistentRCTsB · SomepositiveRCTsC · LimitedD · Lab oranimalX · No effectin good trialsHeart, lipids and blood pressure (167)Heart, lipids and blood pressure, grade A: 11 of 167 findings (7%)7%Heart, lipids and blood pressure, grade B: 62 of 167 findings (37%)37%Heart, lipids and blood pressure, grade C: 77 of 167 findings (46%)46%Heart, lipids and blood pressure, grade D: 0 of 167 findings (0%)0%Heart, lipids and blood pressure, grade X: 17 of 167 findings (10%)10%Blood sugar and weight (128)Blood sugar and weight, grade A: 2 of 128 findings (2%)2%Blood sugar and weight, grade B: 34 of 128 findings (27%)27%Blood sugar and weight, grade C: 84 of 128 findings (66%)66%Blood sugar and weight, grade D: 3 of 128 findings (2%)2%Blood sugar and weight, grade X: 5 of 128 findings (4%)4%Digestion and gut (87)Digestion and gut, grade A: 1 of 87 findings (1%)1%Digestion and gut, grade B: 29 of 87 findings (33%)33%Digestion and gut, grade C: 51 of 87 findings (59%)59%Digestion and gut, grade D: 1 of 87 findings (1%)1%Digestion and gut, grade X: 5 of 87 findings (6%)6%Energy, exercise and muscle (68)Energy, exercise and muscle, grade A: 2 of 68 findings (3%)3%Energy, exercise and muscle, grade B: 17 of 68 findings (25%)25%Energy, exercise and muscle, grade C: 43 of 68 findings (63%)63%Energy, exercise and muscle, grade D: 0 of 68 findings (0%)0%Energy, exercise and muscle, grade X: 6 of 68 findings (9%)9%Inflammation, joints and pain (58)Inflammation, joints and pain, grade A: 0 of 58 findings (0%)0%Inflammation, joints and pain, grade B: 15 of 58 findings (26%)26%Inflammation, joints and pain, grade C: 41 of 58 findings (71%)71%Inflammation, joints and pain, grade D: 1 of 58 findings (2%)2%Inflammation, joints and pain, grade X: 1 of 58 findings (2%)2%Memory and cognition (53)Memory and cognition, grade A: 0 of 53 findings (0%)0%Memory and cognition, grade B: 4 of 53 findings (8%)8%Memory and cognition, grade C: 41 of 53 findings (77%)77%Memory and cognition, grade D: 0 of 53 findings (0%)0%Memory and cognition, grade X: 8 of 53 findings (15%)15%Colds and immune function (42)Colds and immune function, grade A: 2 of 42 findings (5%)5%Colds and immune function, grade B: 8 of 42 findings (19%)19%Colds and immune function, grade C: 28 of 42 findings (67%)67%Colds and immune function, grade D: 0 of 42 findings (0%)0%Colds and immune function, grade X: 4 of 42 findings (10%)10%Cancer research (41)Cancer research, grade A: 0 of 41 findings (0%)0%Cancer research, grade B: 4 of 41 findings (10%)10%Cancer research, grade C: 25 of 41 findings (61%)61%Cancer research, grade D: 1 of 41 findings (2%)2%Cancer research, grade X: 11 of 41 findings (27%)27%Skin, hair and healthy aging (31)Skin, hair and healthy aging, grade A: 0 of 31 findings (0%)0%Skin, hair and healthy aging, grade B: 3 of 31 findings (10%)10%Skin, hair and healthy aging, grade C: 24 of 31 findings (77%)77%Skin, hair and healthy aging, grade D: 1 of 31 findings (3%)3%Skin, hair and healthy aging, grade X: 3 of 31 findings (10%)10%Anxiety, stress and cortisol (28)Anxiety, stress and cortisol, grade A: 1 of 28 findings (4%)4%Anxiety, stress and cortisol, grade B: 7 of 28 findings (25%)25%Anxiety, stress and cortisol, grade C: 19 of 28 findings (68%)68%Anxiety, stress and cortisol, grade D: 0 of 28 findings (0%)0%Anxiety, stress and cortisol, grade X: 1 of 28 findings (4%)4%Menopause (24)Menopause, grade A: 0 of 24 findings (0%)0%Menopause, grade B: 5 of 24 findings (21%)21%Menopause, grade C: 18 of 24 findings (75%)75%Menopause, grade D: 0 of 24 findings (0%)0%Menopause, grade X: 1 of 24 findings (4%)4%Mood and depression (23)Mood and depression, grade A: 1 of 23 findings (4%)4%Mood and depression, grade B: 5 of 23 findings (22%)22%Mood and depression, grade C: 16 of 23 findings (70%)70%Mood and depression, grade D: 0 of 23 findings (0%)0%Mood and depression, grade X: 1 of 23 findings (4%)4%Eyes and vision (23)Eyes and vision, grade A: 0 of 23 findings (0%)0%Eyes and vision, grade B: 4 of 23 findings (17%)17%Eyes and vision, grade C: 13 of 23 findings (57%)57%Eyes and vision, grade D: 0 of 23 findings (0%)0%Eyes and vision, grade X: 6 of 23 findings (26%)26%Fertility and pregnancy (22)Fertility and pregnancy, grade A: 3 of 22 findings (14%)14%Fertility and pregnancy, grade B: 7 of 22 findings (32%)32%Fertility and pregnancy, grade C: 12 of 22 findings (55%)55%Fertility and pregnancy, grade D: 0 of 22 findings (0%)0%Fertility and pregnancy, grade X: 0 of 22 findings (0%)0%Sleep (21)Sleep, grade A: 0 of 21 findings (0%)0%Sleep, grade B: 6 of 21 findings (29%)29%Sleep, grade C: 15 of 21 findings (71%)71%Sleep, grade D: 0 of 21 findings (0%)0%Sleep, grade X: 0 of 21 findings (0%)0%Liver and kidney (18)Liver and kidney, grade A: 0 of 18 findings (0%)0%Liver and kidney, grade B: 2 of 18 findings (11%)11%Liver and kidney, grade C: 14 of 18 findings (78%)78%Liver and kidney, grade D: 1 of 18 findings (6%)6%Liver and kidney, grade X: 1 of 18 findings (6%)6%Urinary tract and prostate (18)Urinary tract and prostate, grade A: 1 of 18 findings (6%)6%Urinary tract and prostate, grade B: 3 of 18 findings (17%)17%Urinary tract and prostate, grade C: 10 of 18 findings (56%)56%Urinary tract and prostate, grade D: 0 of 18 findings (0%)0%Urinary tract and prostate, grade X: 4 of 18 findings (22%)22%Bone health (16)Bone health, grade A: 0 of 16 findings (0%)0%Bone health, grade B: 1 of 16 findings (6%)6%Bone health, grade C: 14 of 16 findings (88%)88%Bone health, grade D: 0 of 16 findings (0%)0%Bone health, grade X: 1 of 16 findings (6%)6%Menstrual pain and PMS (14)Menstrual pain and PMS, grade A: 0 of 14 findings (0%)0%Menstrual pain and PMS, grade B: 5 of 14 findings (36%)36%Menstrual pain and PMS, grade C: 9 of 14 findings (64%)64%Menstrual pain and PMS, grade D: 0 of 14 findings (0%)0%Menstrual pain and PMS, grade X: 0 of 14 findings (0%)0%Headache and migraine (10)Headache and migraine, grade A: 0 of 10 findings (0%)0%Headache and migraine, grade B: 3 of 10 findings (30%)30%Headache and migraine, grade C: 7 of 10 findings (70%)70%Headache and migraine, grade D: 0 of 10 findings (0%)0%Headache and migraine, grade X: 0 of 10 findings (0%)0%Share of the row's findings0%100%Heat map of grade shares by studied effect for effects with 10 or more findings; the data table lists every valueEffect studied (findings)ABCDXHeart, lipids and bloodpressure (167)Heart, lipids and blood pressure, grade A: 11 of 167 findings (7%)7%Heart, lipids and blood pressure, grade B: 62 of 167 findings (37%)37%Heart, lipids and blood pressure, grade C: 77 of 167 findings (46%)46%Heart, lipids and blood pressure, grade D: 0 of 167 findings (0%)0%Heart, lipids and blood pressure, grade X: 17 of 167 findings (10%)10%Blood sugar and weight(128)Blood sugar and weight, grade A: 2 of 128 findings (2%)2%Blood sugar and weight, grade B: 34 of 128 findings (27%)27%Blood sugar and weight, grade C: 84 of 128 findings (66%)66%Blood sugar and weight, grade D: 3 of 128 findings (2%)2%Blood sugar and weight, grade X: 5 of 128 findings (4%)4%Digestion and gut (87)Digestion and gut, grade A: 1 of 87 findings (1%)1%Digestion and gut, grade B: 29 of 87 findings (33%)33%Digestion and gut, grade C: 51 of 87 findings (59%)59%Digestion and gut, grade D: 1 of 87 findings (1%)1%Digestion and gut, grade X: 5 of 87 findings (6%)6%Energy, exercise andmuscle (68)Energy, exercise and muscle, grade A: 2 of 68 findings (3%)3%Energy, exercise and muscle, grade B: 17 of 68 findings (25%)25%Energy, exercise and muscle, grade C: 43 of 68 findings (63%)63%Energy, exercise and muscle, grade D: 0 of 68 findings (0%)0%Energy, exercise and muscle, grade X: 6 of 68 findings (9%)9%Inflammation, joints andpain (58)Inflammation, joints and pain, grade A: 0 of 58 findings (0%)0%Inflammation, joints and pain, grade B: 15 of 58 findings (26%)26%Inflammation, joints and pain, grade C: 41 of 58 findings (71%)71%Inflammation, joints and pain, grade D: 1 of 58 findings (2%)2%Inflammation, joints and pain, grade X: 1 of 58 findings (2%)2%Memory and cognition(53)Memory and cognition, grade A: 0 of 53 findings (0%)0%Memory and cognition, grade B: 4 of 53 findings (8%)8%Memory and cognition, grade C: 41 of 53 findings (77%)77%Memory and cognition, grade D: 0 of 53 findings (0%)0%Memory and cognition, grade X: 8 of 53 findings (15%)15%Colds and immunefunction (42)Colds and immune function, grade A: 2 of 42 findings (5%)5%Colds and immune function, grade B: 8 of 42 findings (19%)19%Colds and immune function, grade C: 28 of 42 findings (67%)67%Colds and immune function, grade D: 0 of 42 findings (0%)0%Colds and immune function, grade X: 4 of 42 findings (10%)10%Cancer research (41)Cancer research, grade A: 0 of 41 findings (0%)0%Cancer research, grade B: 4 of 41 findings (10%)10%Cancer research, grade C: 25 of 41 findings (61%)61%Cancer research, grade D: 1 of 41 findings (2%)2%Cancer research, grade X: 11 of 41 findings (27%)27%Skin, hair and healthyaging (31)Skin, hair and healthy aging, grade A: 0 of 31 findings (0%)0%Skin, hair and healthy aging, grade B: 3 of 31 findings (10%)10%Skin, hair and healthy aging, grade C: 24 of 31 findings (77%)77%Skin, hair and healthy aging, grade D: 1 of 31 findings (3%)3%Skin, hair and healthy aging, grade X: 3 of 31 findings (10%)10%Anxiety, stress andcortisol (28)Anxiety, stress and cortisol, grade A: 1 of 28 findings (4%)4%Anxiety, stress and cortisol, grade B: 7 of 28 findings (25%)25%Anxiety, stress and cortisol, grade C: 19 of 28 findings (68%)68%Anxiety, stress and cortisol, grade D: 0 of 28 findings (0%)0%Anxiety, stress and cortisol, grade X: 1 of 28 findings (4%)4%Menopause (24)Menopause, grade A: 0 of 24 findings (0%)0%Menopause, grade B: 5 of 24 findings (21%)21%Menopause, grade C: 18 of 24 findings (75%)75%Menopause, grade D: 0 of 24 findings (0%)0%Menopause, grade X: 1 of 24 findings (4%)4%Mood and depression(23)Mood and depression, grade A: 1 of 23 findings (4%)4%Mood and depression, grade B: 5 of 23 findings (22%)22%Mood and depression, grade C: 16 of 23 findings (70%)70%Mood and depression, grade D: 0 of 23 findings (0%)0%Mood and depression, grade X: 1 of 23 findings (4%)4%Eyes and vision (23)Eyes and vision, grade A: 0 of 23 findings (0%)0%Eyes and vision, grade B: 4 of 23 findings (17%)17%Eyes and vision, grade C: 13 of 23 findings (57%)57%Eyes and vision, grade D: 0 of 23 findings (0%)0%Eyes and vision, grade X: 6 of 23 findings (26%)26%Fertility and pregnancy(22)Fertility and pregnancy, grade A: 3 of 22 findings (14%)14%Fertility and pregnancy, grade B: 7 of 22 findings (32%)32%Fertility and pregnancy, grade C: 12 of 22 findings (55%)55%Fertility and pregnancy, grade D: 0 of 22 findings (0%)0%Fertility and pregnancy, grade X: 0 of 22 findings (0%)0%Sleep (21)Sleep, grade A: 0 of 21 findings (0%)0%Sleep, grade B: 6 of 21 findings (29%)29%Sleep, grade C: 15 of 21 findings (71%)71%Sleep, grade D: 0 of 21 findings (0%)0%Sleep, grade X: 0 of 21 findings (0%)0%Liver and kidney (18)Liver and kidney, grade A: 0 of 18 findings (0%)0%Liver and kidney, grade B: 2 of 18 findings (11%)11%Liver and kidney, grade C: 14 of 18 findings (78%)78%Liver and kidney, grade D: 1 of 18 findings (6%)6%Liver and kidney, grade X: 1 of 18 findings (6%)6%Urinary tract and prostate(18)Urinary tract and prostate, grade A: 1 of 18 findings (6%)6%Urinary tract and prostate, grade B: 3 of 18 findings (17%)17%Urinary tract and prostate, grade C: 10 of 18 findings (56%)56%Urinary tract and prostate, grade D: 0 of 18 findings (0%)0%Urinary tract and prostate, grade X: 4 of 18 findings (22%)22%Bone health (16)Bone health, grade A: 0 of 16 findings (0%)0%Bone health, grade B: 1 of 16 findings (6%)6%Bone health, grade C: 14 of 16 findings (88%)88%Bone health, grade D: 0 of 16 findings (0%)0%Bone health, grade X: 1 of 16 findings (6%)6%Menstrual pain and PMS(14)Menstrual pain and PMS, grade A: 0 of 14 findings (0%)0%Menstrual pain and PMS, grade B: 5 of 14 findings (36%)36%Menstrual pain and PMS, grade C: 9 of 14 findings (64%)64%Menstrual pain and PMS, grade D: 0 of 14 findings (0%)0%Menstrual pain and PMS, grade X: 0 of 14 findings (0%)0%Headache and migraine(10)Headache and migraine, grade A: 0 of 10 findings (0%)0%Headache and migraine, grade B: 3 of 10 findings (30%)30%Headache and migraine, grade C: 7 of 10 findings (70%)70%Headache and migraine, grade D: 0 of 10 findings (0%)0%Headache and migraine, grade X: 0 of 10 findings (0%)0%Share of the row's findings0%100%
Data table: grade by effect studied
Findings by studied effect and grade (count and row share)
Effect studiedIngredientsFindingsABCDXC or X
Heart, lipids and blood pressure10516711 (7%)62 (37%)77 (46%)0 (0%)17 (10%)56%
Blood sugar and weight861282 (2%)34 (27%)84 (66%)3 (2%)5 (4%)70%
Digestion and gut38871 (1%)29 (33%)51 (59%)1 (1%)5 (6%)64%
Energy, exercise and muscle45682 (3%)17 (25%)43 (63%)0 (0%)6 (9%)72%
Inflammation, joints and pain37580 (0%)15 (26%)41 (71%)1 (2%)1 (2%)72%
Memory and cognition41530 (0%)4 (8%)41 (77%)0 (0%)8 (15%)92%
Colds and immune function27422 (5%)8 (19%)28 (67%)0 (0%)4 (10%)76%
Cancer research30410 (0%)4 (10%)25 (61%)1 (2%)11 (27%)88%
Skin, hair and healthy aging23310 (0%)3 (10%)24 (77%)1 (3%)3 (10%)87%
Anxiety, stress and cortisol20281 (4%)7 (25%)19 (68%)0 (0%)1 (4%)71%
Menopause18240 (0%)5 (21%)18 (75%)0 (0%)1 (4%)79%
Mood and depression18231 (4%)5 (22%)16 (70%)0 (0%)1 (4%)74%
Eyes and vision15230 (0%)4 (17%)13 (57%)0 (0%)6 (26%)83%
Fertility and pregnancy20223 (14%)7 (32%)12 (55%)0 (0%)0 (0%)55%
Sleep16210 (0%)6 (29%)15 (71%)0 (0%)0 (0%)71%
Liver and kidney15180 (0%)2 (11%)14 (78%)1 (6%)1 (6%)83%
Urinary tract and prostate8181 (6%)3 (17%)10 (56%)0 (0%)4 (22%)78%
Bone health13160 (0%)1 (6%)14 (88%)0 (0%)1 (6%)94%
Menstrual pain and PMS12140 (0%)5 (36%)9 (64%)0 (0%)0 (0%)64%
Headache and migraine7100 (0%)3 (30%)7 (70%)0 (0%)0 (0%)70%

Left out for fewer than 10 findings: Hydration and electrolytes (2) . Findings without an effect tag are counted in the totals above but not in this table.

Effect tags describe what was studied, never a benefit; they build the Supplements by effect pages.EUTECNIQ Supplements A–Z data.
Grade shares by the ingredient's evidence class: in Class 1, the best-studied ingredients, 57% of findings are C Site data, editorial grades
Heat map of grade shares by evidence class: Class 1: Well studied in people 57% C of 730 findings; Class 2: Moderately studied in people 85% C of 271 findings; Class 3: Limited studies in people 78% C of 63 findings; Class 4: Animal studies only 0% C of 7 findingsEvidence class (findings)A ·ConsistentRCTsB · SomepositiveRCTsC · LimitedD · Lab oranimalX · No effectin good trialsClass 1: Well studied in people (730)Class 1: Well studied in people, grade A: 27 of 730 findings (4%)4%Class 1: Well studied in people, grade B: 212 of 730 findings (29%)29%Class 1: Well studied in people, grade C: 417 of 730 findings (57%)57%Class 1: Well studied in people, grade D: 2 of 730 findings (0%)0%Class 1: Well studied in people, grade X: 72 of 730 findings (10%)10%Class 2: Moderately studied in people (271)Class 2: Moderately studied in people, grade A: 0 of 271 findings (0%)0%Class 2: Moderately studied in people, grade B: 26 of 271 findings (10%)10%Class 2: Moderately studied in people, grade C: 229 of 271 findings (85%)85%Class 2: Moderately studied in people, grade D: 4 of 271 findings (1%)1%Class 2: Moderately studied in people, grade X: 12 of 271 findings (4%)4%Class 3: Limited studies in people (63)Class 3: Limited studies in people, grade A: 0 of 63 findings (0%)0%Class 3: Limited studies in people, grade B: 1 of 63 findings (2%)2%Class 3: Limited studies in people, grade C: 49 of 63 findings (78%)78%Class 3: Limited studies in people, grade D: 12 of 63 findings (19%)19%Class 3: Limited studies in people, grade X: 1 of 63 findings (2%)2%Class 4: Animal studies only (7)Class 4: Animal studies only, grade A: 0 of 7 findings (0%)0%Class 4: Animal studies only, grade B: 0 of 7 findings (0%)0%Class 4: Animal studies only, grade C: 0 of 7 findings (0%)0%Class 4: Animal studies only, grade D: 7 of 7 findings (100%)100%Class 4: Animal studies only, grade X: 0 of 7 findings (0%)0%Share of the row's findings0%100%Heat map of grade shares by evidence class: Class 1: Well studied in people 57% C of 730 findings; Class 2: Moderately studied in people 85% C of 271 findings; Class 3: Limited studies in people 78% C of 63 findings; Class 4: Animal studies only 0% C of 7 findingsEvidence class(findings)ABCDXClass 1: Well studied inpeople (730)Class 1: Well studied in people, grade A: 27 of 730 findings (4%)4%Class 1: Well studied in people, grade B: 212 of 730 findings (29%)29%Class 1: Well studied in people, grade C: 417 of 730 findings (57%)57%Class 1: Well studied in people, grade D: 2 of 730 findings (0%)0%Class 1: Well studied in people, grade X: 72 of 730 findings (10%)10%Class 2: Moderatelystudied in people (271)Class 2: Moderately studied in people, grade A: 0 of 271 findings (0%)0%Class 2: Moderately studied in people, grade B: 26 of 271 findings (10%)10%Class 2: Moderately studied in people, grade C: 229 of 271 findings (85%)85%Class 2: Moderately studied in people, grade D: 4 of 271 findings (1%)1%Class 2: Moderately studied in people, grade X: 12 of 271 findings (4%)4%Class 3: Limited studiesin people (63)Class 3: Limited studies in people, grade A: 0 of 63 findings (0%)0%Class 3: Limited studies in people, grade B: 1 of 63 findings (2%)2%Class 3: Limited studies in people, grade C: 49 of 63 findings (78%)78%Class 3: Limited studies in people, grade D: 12 of 63 findings (19%)19%Class 3: Limited studies in people, grade X: 1 of 63 findings (2%)2%Class 4: Animal studiesonly (7)Class 4: Animal studies only, grade A: 0 of 7 findings (0%)0%Class 4: Animal studies only, grade B: 0 of 7 findings (0%)0%Class 4: Animal studies only, grade C: 0 of 7 findings (0%)0%Class 4: Animal studies only, grade D: 7 of 7 findings (100%)100%Class 4: Animal studies only, grade X: 0 of 7 findings (0%)0%Share of the row's findings0%100%
Data table: grade by evidence class
Findings by the ingredient's evidence class and grade (count and row share)
Evidence classIngredientsFindingsABCDXC or X
Class 1: Well studied in people17373027 (4%)212 (29%)417 (57%)2 (0%)72 (10%)67%
Class 2: Moderately studied in people662710 (0%)26 (10%)229 (85%)4 (1%)12 (4%)89%
Class 3: Limited studies in people22630 (0%)1 (2%)49 (78%)12 (19%)1 (2%)79%
Class 4: Animal studies only370 (0%)0 (0%)0 (0%)7 (100%)0 (0%)0%
The class counts studies of the ingredient taken alone; the grade judges each studied topic. A well-studied ingredient can still have limited evidence for many of the topics studied.EUTECNIQ Supplements A–Z data.

An X grade needs well-designed trials that found no effect; the vitamin category has the highest X share (31% of 70 rows). Botanical rows mostly sit at C (398 of 522), limited or mixed human evidence. For Class 1, the best-studied ingredients, 57% of rows are C.

Closing the gap

Five practices that answer six of the seven causes

Each practice below is already a published standard or policy; together they reach six of the seven causes, and the seventh, who pays, is a question of law and funding.

Which practice addresses which causePublished standards; mapping is editorial
Matrix of five practices against seven causes: characterized material addresses product variation; powered trials address small trials; registration addresses unclear endpoints and positive-result bias; CONSORT-herbal reporting addresses incomplete reports; pharmacokinetics first addresses low exposure; no practice addresses who paysProduct variesTrials smallReportsincompleteEndpointsunclearLow exposurePositive biasWho paysCharacterized, standardized materialCharacterized, standardized material · Product varies: highCharacterized, standardized material · Reports incomplete: mediumAdequately powered trialsAdequately powered trials · Trials small: highAdequately powered trials · Positive bias: mediumRegistration before enrollmentRegistration before enrollment · Reports incomplete: mediumRegistration before enrollment · Endpoints unclear: highRegistration before enrollment · Positive bias: highCONSORT-herbal reportingCONSORT-herbal reporting · Product varies: mediumCONSORT-herbal reporting · Reports incomplete: highCONSORT-herbal reporting · Endpoints unclear: mediumPharmacokinetics before efficacyPharmacokinetics before efficacy · Endpoints unclear: mediumPharmacokinetics before efficacy · Low exposure: highMatrix of seven causes against five numbered practices; no practice addresses who pays12345Product variesProduct varies · 1: highProduct varies · 4: mediumTrials smallTrials small · 2: highReports incompleteReports incomplete · 1: mediumReports incomplete · 3: mediumReports incomplete · 4: highEndpoints unclearEndpoints unclear · 3: highEndpoints unclear · 4: mediumEndpoints unclear · 5: mediumLow exposureLow exposure · 5: highPositive biasPositive bias · 2: mediumPositive bias · 3: highWho pays1 Characterized, standardized material2 Adequately powered trials3 Registration before enrollment4 CONSORT-herbal reporting5 Pharmacokinetics before efficacy
A filled circle marks a practice that addresses the cause directly, a half-filled circle one that addresses it in part, and a dash no effect. The mapping is the site's editorial reading of the sources below.NIH ODS, The Importance of Natural Product Characterization and Integrity for Dietary Supplement Research; Sakpal 2010; Lakens 2013; ICMJE, Clinical Trial Registration; Gagnier et al. 2006; FDA Botanical Drug Development guidance (2016), Sections V.D and V.E.
Text version: the five practices and their sources
  1. Characterized, standardized material. NIH's Office of Dietary Supplements states that “reproducible research on natural products (NPs) requires the use of replicable, well-characterized NP preparations,” with authentication of identity and assessment of composition, purity and stability. What “standardized” does and does not mean on a label is on How to judge a supplement.
  2. Adequately powered trials. The sample size is calculated before the trial from the expected difference, its standard deviation, α and power (Sakpal 2010); 0.80 is the generally accepted minimum power (Lakens 2013). The calculator above shows the scale involved.
  3. Registration before enrollment. ICMJE recommends that journal editors require registration of clinical trials in a public registry “at or before the time of first patient consent for enrollment” as a condition of consideration for publication; its examples of health-related interventions include dietary interventions. A registered protocol fixes the primary outcome and makes unpublished trials visible.
  4. CONSORT reporting with the herbal extension. The 2006 extension elaborates 9 CONSORT items; the elaboration of item 4 “outlines specific information required for complete reporting of the herbal medicine intervention” (Gagnier et al., Explore 2006).
  5. Pharmacokinetics before efficacy. FDA's botanical guidance says that when the major active constituents are known, the sponsor “should attempt to measure the blood levels” of them; that an approach based on a pharmacodynamic or clinical endpoint may be appropriate if no quantifiable active constituents are available (Section V.D); and that a clinical dose-response study may be necessary when the dose is uncertain (Section V.E). Why exposure comes before benefit is set out on Absorption is not efficacy.

NIH ODS, Funding: The Importance of Natural Product Characterization and Integrity for Dietary Supplement Research (no date printed; read October 30, 2026). ICMJE, Clinical Trial Registration (journal policy, not law). Gagnier JJ, et al. Ann Intern Med 2006;144:364–367, Explore 2006;2:143–149 and J Clin Epidemiol 2006;59:1134–1149. FDA Botanical Drug Development guidance, December 2016.

How EUTECNIQ would apply this Proposal

EUTECNIQ proposes to supply trial material with documented identity, a validated marker assay and batch records; to plan human studies with a written power calculation, registration before enrollment and CONSORT-herbal reporting; and to place pharmacokinetic studies before efficacy trials, with clinical work run by qualified external partners. None of this exists yet.

Planning human evidence for a botanical?

Proposal EUTECNIQ proposes evidence plans that start from characterized material and an honest power calculation.

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]